Johnson & Johnson (NYSE: JNJ) reported that guselkumab (Tremfya) met the primary endpoint of combined fistula remission in the Phase III FUZION study in adults with active perianal fistulizing Crohn's disease, positioning it as the first IL-23 inhibitor to demonstrate efficacy in an indication where the only approved systemic options have, for more than two decades, been anti-TNF agents.
The FUZION study (NCT05347095) is a randomized, double-blind, placebo-controlled, multicenter Phase III trial evaluating guselkumab in adults with one or more active draining perianal fistulas confirmed by blinded central MRI review.
At Week 24, combined fistula remission — defined as complete closure of all external fistula openings with no drainage, no new fistulas, and no evidence of underlying fluid collections on MRI — was achieved by 28.3% of patients receiving guselkumab 100 mg every 8 weeks and 27.0% of those receiving 200 mg every 4 weeks, compared with 10.3% for placebo. Both dosing regimens reached statistical significance versus placebo (p=0.007 and p=0.013, respectively). Adverse events through Week 24 were consistent with guselkumab's established safety profile in Crohn's disease; no numerical breakdown was disclosed in the announcement.
The magnitude of the treatment effect — roughly a 17–18 percentage point absolute difference over placebo — is notable given the stringency of the endpoint, which required both clinical and radiographic confirmation of remission. That MRI-confirmed component matters: earlier fistula trials in Crohn's disease have used clinical closure alone as the primary measure, which can overestimate true healing by missing residual subcutaneous collections. The FUZION endpoint design therefore sets a higher evidentiary bar than some historical comparators, though cross-trial comparisons are limited by differences in population, endpoint definitions, and background therapy.
Perianal fistulizing Crohn's disease affects approximately 25% of patients with Crohn's disease and carries a substantial burden of pain, recurrent abscess formation, and repeated surgical intervention. Despite that prevalence, the condition has been largely absent from dedicated randomized trial programs. The last major controlled study of an approved therapy in this population was conducted more than 20 years ago — the ACCENT II trial of Johnson & Johnson's Remicade (infliximab), which established infliximab as the first biologic approved specifically for fistulizing Crohn's disease in 1999. AbbVie's Humira (adalimumab) subsequently became a clinical standard based on fistula closure data from the CHARM trial, though its label language for the fistulizing subtype is less explicit than infliximab's. Both approved systemic options act through TNF-α inhibition, leaving patients who fail or cannot tolerate anti-TNF therapy without an approved systemic alternative in the US for this specific manifestation.
Guselkumab works through a distinct mechanism. It is a fully human monoclonal antibody targeting the p19 subunit of interleukin-23, blocking IL-23 signaling and the downstream Th17-driven inflammatory cascade implicated in both luminal and perianal Crohn's disease pathology. The company also describes a secondary binding interaction with CD64, a receptor expressed on IL-23-producing inflammatory monocytes, though the clinical relevance of that interaction remains uncharacterized beyond in vitro data.